ALS Investment Fund Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 2
- Investments
- 9
- Portfolio
- 6
- Exits
- 2
ALS Investment Fund General Information
Description
Founded in 2016, ALS Investment Fund is a venture capital fund based in Amsterdam, Netherlands. The firm supports and finances biotech companies that develop drugs and diagnostics for the disease ALS (also called Lou Gehrig's disease). The firm makes investments during the later development stage with proven science, preference on clinical stage investments (Phase I or II), and Series A and B.
Contact Information
Website
www.alsinvestmentfund.com
Year Founded
2016
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital
Primary Office
- Kerkstraat 342
- 1017 JA Amsterdam
- Netherlands
+31 020 000 0000
ALS Investment Fund Investments (9)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Verge Genomics | 15-Dec-2021 | Later Stage VC | 0000 | Drug Discovery | Pre-Clinical Trials | |
| 00000 0000000 | 09-Dec-2021 | 00000 00000 | 0000 | Drug Discovery | Generating Revenue | 00000 000 0000000 |
| 00000000 000000000 | 03-Nov-2021 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - Phase 3 | |
| 0000 000 | 11-Nov-2020 | 00000 00000 | 000.00 | Drug Discovery | Pre-Clinical Trials | 000000 0000000-000 000000 |
| 00000000 000000000 | 03-Jun-2020 | 00000 00000 | 000.00 | Drug Discovery | Clinical Trials - Phase 3 | |
| 00000 00000000 | 16-Jul-2018 | 00000 00000 | 0000 | Drug Discovery | Pre-Clinical Trials | 0000000 0000000 00.0 |
| 0000000 | 19-Jun-2018 | 00000 00000 | 0000 | Biotechnology | Generating Revenue | |
| Orphazyme | 08-Mar-2017 | Later Stage VC | 000.00 | Biotechnology | Generating Revenue | |
| Amylyx | 22-Aug-2016 | Early Stage VC | 000 | Drug Discovery | Clinical Trials - Phase 3 | 00000 000 0000000 |
ALS Investment Fund Exits (2)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Amylyx | 07-Jan-2022 | IPO | 00000 |
| 000000000 | 21-Nov-2017 | 000 | 000.00 |
ALS Investment Fund Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialALS Investment Fund Team (16)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Melanie Leitner Ph.D | Consultant | 0 | 0 | New York, NY | |
| Felix von Coerper | Fund Manager, Investments | 0 | 0 | 0 | New York, NY |
| Jeff Rothstein | Member of Scientific Advisory Board | New York, NY | |||
| Leonard van den Berg MD | Member of Scientific Advisory Board | Amsterdam, Netherlands | |||
| Merit Cudkowicz | Member of Scientific Advisory Board | New York, NY |
ALS Investment Fund Co-Investors (39)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| 5Y Capital | 2 | 0 |
|
|
|
| BlackRock | 0 | 0 |
|
|
|
| Forbion | 0 | 0 |
|
|
|
| Sectoral Asset Management | 0 | 0 |
|
|
|
| The Ropart Asset Management Funds | 0 |
|
|